\
&
Contact us
\
&
Contact us
This was 5 months ago
LocationBrussels
The Commission together with the European Society of Radiology and EUCAIM is organising an event exploring how the European Cancer Imaging Initiative harnesses health data and Artificial Intelligence to advance the fight against cancer.
Two years after the launch of the European Cancer Imaging Initiative, Member States and stakeholders from research, innovation and healthcare organisations, will explore perspectives for the Initiative’s contribution to advancing trustworthy AI tools for precision oncology and its role in the future European Health Data Space.
At the heart of this Initiative is the Cancer Image Europe Infrastructure under development by the EUCAIM project. By 2026, the infrastructure will provide researchers, innovators and clinicians with secure access to extensive cancer image datasets, unlocking the potential for AI tools to detect cancer sooner and faster, and treat the patients more accurately.
At the event, EUCAIM will share major milestones, introduce new project partners, and discuss progress towards the establishment of an EUCAIM EDIC (European Digital Infrastructure Consortium).
Target audience: This event aims to bring together key figures in the digital transformation of healthcare across EU Member States, including representatives from health ministries, digital health agencies, hospitals, and cancer research institutes. The event also welcomes researchers and SMEs working with imaging data to gain and provide valuable insights on AI innovation in cancer diagnostics and treatment.
The detailed agenda and the registration link are available on this page .
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
